Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looks like AZ has followed suit and added small Gracell to its portfolio for a mere $1.2bn.
It is about $1bn when Gs cash is taken off.
Probably cheaper than licensing in the long run…
Added, small.
'R&D success gives AstraZeneca a shot in the arm', they said.
..
Now I am worried!
Tipped as a “buy” in today’s Questor column Daily Telegraph.
All of the Covid vaccine producing companies were granted legal indemnity.
Scientists have drawn a link between the Oxford-AstraZeneca vaccine and a “spike” in cases of a rare disease that can leave its victims paralysed.
Three separate studies reported an increase in Guillain-Barré syndrome (GBS) shortly after the roll out of the AstraZeneca vaccine.
https://www.msn.com/en-gb/health/other/astrazeneca-vaccine-linked-with-spike-in-cases-of-rare-disease-that-can-paralyse-victims/ar-AA1ldmba
Not so good news, Is it?
Can you imagine the payouts and the legal costs?
Not so fast perhaps. Could slip back to £100. Depends on mood for FTSE 100
Bought a nice 166 shares today - She's going up!
Sorry mate.
Didn't understand what you was saying.
A bit cryptic for me. I'm from Yorkshire & we just say it how it is. :-)
Now is the time to buy!
"Confused" is a tad overgenerous given his previous post regarding "A string of failures lately". Math is obviously another weak point. One to file under "ignore" LOL
Added 200 more shares here this morning. Future is bright.
Being shorted .
Love it. :-)
[hint: “… now under 10£…” - have you checked where the decimal point comes with this share?]
“… two years ago this share was 30£ …”
i think winkleberry is confused, at best.
What is going on two years ago this share was 30£ now under 10£ alarm bells should be ringing, I still believe this is a great share but not for the faint hearted.this was once the toast of the Fste 100.A good time to buy I hope, alot of brokers have not got this wrong! They believe in Astra Zeneca.
....Finally gone below 100. Hope it's not signs of an even longer slippery slope?
It's a hold for me. Could take some large profits here today, but will hold for some more gold.
From low 10's to low 11's.... Three week hold?
Well said grayling. Share price failing ( as most others have ) but a lot of lives being saved. Hopefully, I'll never have to use any AZN meds ! Have a great weekend
What "string of failures" are you talking about? Since July this year these are the clinical trial and product updates:
Imfinzi combination improves PFS in liver cancer
Dato-DXd improved PFS in breast cancer
Enhertu recommended in EU for HER2-mutant NSCLC
Fasenra Phase III EGPA trial met primary endpoint
Beyfortus approved in US for infant RSV prevention
Against this you have ONE failure and that is in end-stage (non-resectable) non-small cell lung cancer (NSCLC) one of the most intractable and inevitably terminal forms of lung cancer. Can't you read?
We could do with some good news, there has been a string of failures lately, I know this is a high tech stock I am in two minds to bail out there are safer havens let's hope the slimming pil is a great success.